Nov 05, 2014: As regulatory hurdles increase and product pipelines shrink, pharmaceutical companies must identify new revenue drivers to maintain growth. Addressing patient non-adherence and thereby improving health outcomes, seems like a popular answer to the problem, yet improving patient adherence is an incommodious task.

Outside link:
Pharma companies in the US alone are trying to fight non-adherence costs of more than $290 billion